Taj pharmaceuticals limited, 90 state street, suite 700 albany, ny 12207

MEDGADGET



ECHOJOURNAL

POPULAR

PASSMIX

CATEGORIES

SUBSCRIBE



SUBMIT

ABOUT

+ FOLLOW

✏ SUBMIT PR





* LOG IN









Erdosteine Market – Future Growth, Opportunities and Forecast To 2024 

MARCH 7TH, 2017

 Facebook

TRANSPARENCY MARKET RESEARCH

  Twitter

  Google+



RELEASES

  LinkedIn

RECENT POSTS Jet Powered Pill Shoots Vaccine Into Cheek to Avoid Injections

PDFmyURL - online url to pdf conversion

Erdosteine is an oral mucolytic agent used for treatment of

ZOLL's Hospital Wearable Defibrillator FDA Approved

chronic obstructive bronchitis. Erdosteine is also used for treatment of acute and chronic bronchitis. It is an orphan drug. Erdosteine stimulates mucus

Japanese Researchers Develop New Filter to Use microRNA as Disease Biomarker

production and increases mucociliary transport, which improves expectoration. It consists of two sulfhydryl groups

Tiny Paper Pumps to Power Microfluidic Devices

freed after metabolic transformation in the liver. These released sulfhydryl groups help to break the disulphide bonds. This makes bronchial secretions more fluid and enhances elimination. Erdosteine shows inhibitory activity against the effects of free radicals produced by cigarette smoke. Pharmacokinetically,

Method Spots Bacterial Infections in Root Canals to Improve Success, Prevent Additional Procedures

it acts by absorption, distribution, metabolism, and excretion. The elimination half-life of Erdosteine is about 1.46 hr. Adverse events of Erdosteine are quite low, and generally mild. It has been clinically proven that Erdosteine has good gastric tolerability after oral administration, and does not cause reflux phenomena like other thiols derivatives. Erdosteine has no direct effect on

INTERV IEWS & REV IEWS Koogeek S1 Smart Health Scale Review

gastric mucus. Obtain Report Details @ h ttp://w w w .tran sparen cy m ark etresearch .com /erdostein e-m ark et.h tm l Increasing prevalence of respiratory diseases, rising geriatric population, rapid population growth, and environmental pollution due to industrialization are expected to fuel the global erdosteine market. According to the WH O, chronic obstructive pulmonary disease (COPD) accounts for three PDFmyURL - online url to pdf conversion

Medgadget's Coverage of the Inaugural AdvaMed Digital MedTech Conference

million deaths globally each year and the number is expected to increase in the next few years. About 90% of chronic obstructive pulmonary disease (COPD) deaths occur in developing and underdeveloped countries. Rising research and development activities, increasing health care insurance coverage, and growing adoption for treatment options are the other factors driving the global erdosteine market. On the other hand, stringent regulations for product approval are likely to hamper the growth of the global erdosteine

Anders Wold, GE Healthcareâ&#x20AC;&#x2122;s CEO of Clinical Care Solutions on What To Think About When Running a Medtech Business

CleanSlate UV Sanitizer for Mobile Devices in Healthcare: An Interview

market. Erdosteine is used for rare diseases so maximum companies doing research and development which will increase the market competitiveness. Erdosteine is marketed in over 40 countries for the treatment of various respiratory diseases. The erdosteine market has been segmented based on dosage form, age group, application, distribution channel, and region. In terms of dosage form, the market has been classified into capsules, dry suspension, dispersible tablets, and sachets. The capsule dosage form is highly used due to ease of use, availability in unit dosage form, and also easy in term of prescription scenario which will leads to less side effect. Based on age group, the erdosteine market has been segmented into adult and pediatric. In terms of application, the market has been classified into chronic obstructive pulmonary disease (COPD), acute bronchitis (AB), and chronic bronchitis (CB). Based on distribution channel, the erdosteine market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. In terms of region, the market has been segmented into N orth America, Latin America, Europe, Asia Pacific, and Middle East & Africa. N orth America dominated the erdosteine market due to rising geriatric population, early adoption of treatment procedures, and increasing prevalence of respiratory diseases. The geriatric population represents about 14.5% of the population of the U.S. According to the U.S. Department of H ealth and H uman Service, the geriatric population will increase to 98 million by 2060, which is PDFmyURL - online url to pdf conversion

Improving Patient Engagement through Artificial Intelligence: Interview with Gilad Meiri, CEO & Co-Founder of Neura

twice that in 2014. Europe is the second largest market for erdosteine attributed to increasing research and development activities and rising number of commercial licensing partnerships for erdosteine manufacturing. Asia Pacific is expected to grow at a higher rate driven by growing per capita expenditure, increasing health care insurance coverage, rapidly growing population, and rising per capita health care expenditure. Mak e an En quiry @ h ttp://w w w .tran sparen cy m ark etresearch .com /sam ple/sam ple.ph p? flag=B& rep_id=19166 Major players operating in the erdosteine market include Edmond Pharma S.R.L., Alitair Pharmaceuticals, Manus Aktteva Biopharma LLP, Enaltec, Reine Life Science, Taj Pharmaceuticals Ltd., Recipharm AB, Glenmark Pharmaceuticals Ltd., Sigma-Aldrich Co. LLC, Genome Pharmaceuticals (Pvt.) Ltd., and Milan Pharma. U S Office Con tact 90 State Street, Suite 700 Albany, N Y 12207 Tel: +1-518-618-1030 USA â&#x20AC;&#x201C; Canada Toll Free: 866-552-3453 Em ail: sales@ tran sparen cy m ark etresearch .com W ebsite: h ttp://w w w .tran sparen cy m ark etresearch .com /

PDFmyURL - online url to pdf conversion

Sign up and submit a press release